Bromodomain and Extra-Terminal (BET) proteins are a conserved family of ‘epigenetic readers’ that bind to acetylated lysine residues on histone and non-histone proteins to modulate transcription. BET proteins are enriched ...

Breast cancer is the most common cancer in women. Despite advances in treatment options, the spread of breast cancer to distant organs (metastasis) remains the major cause of morbidity and mortality in breast cancer patients. ...

The central theme of this thesis is developing therapeutic strategies to selectively target CCNE1 amplified high grade serous ovarian cancer (HGSC). Patients with CCNE1 amplified HGSC represent a key unmet clinical need ...

Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class, epigenetic targeted therapies that deliver a new therapeutic paradigm by directly targeting protein-protein interactions at chromatin. Early ...

Despite the success of autologous chimeric antigen receptor (CAR) T cells to treat patients with refractory B cell acute lymphoblastic leukaemia, (ALL) and lymphoma, there are many aspects of CAR T cell biology that remains ...

Oesophageal adenocarcinoma (OAC) is a lethal disease with a rapidly rising incidence. The standard of care for patients with early stage OAC is surgery combined with either neoadjuvant chemo-radiotherapy or perioperative ...

Background: The rising prevalence of prostate cancer in Australia will increasingly contribute significant morbidity, mortality and economic burden on society. Radical prostatectomy is the mainstay of treatment for localised ...

Infections are a leading cause of morbidity and mortality in patients with myeloma (MM). Increased risk for infections is due to a range of patient-, disease- and treatment-related factors. The major change in the management ...

Aggressive B-cell lymphomas include diffuse large B-cell lymphoma, Burkitt lymphoma and intermediate forms. Despite high response rates to conventional immuno-chemotherapeutic approaches, an unmet need for novel therapeutic ...

B-cell acute lymphoblastic leukemia (B-ALL) is a malignant neoplasm of B-lymphoid progenitor cells and accounts for approximately 70% of all childhood ALL (Loh and Mullighan, 2012). Overall clinical outcomes for ALL patients ...